These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 13729934)

  • 1. [The products of degradation of human fibrinogen by plasmin. I. Separation and physicochemical properties].
    NUSSENZWEIG V; SELIGMANN M; PELMONT J; GRABAR P
    Ann Inst Pasteur (Paris); 1961 Mar; 100():377-89. PubMed ID: 13729934
    [No Abstract]   [Full Text] [Related]  

  • 2. [Analysis, by immuno-chemical methods, of the degradation by plasmin of human fibrinogen and fibrin, at different stages].
    NUSSENZWEIG V; SELIGMANN M
    Nouv Rev Fr Hematol; 1960; 15():451-66. PubMed ID: 13729935
    [No Abstract]   [Full Text] [Related]  

  • 3. Electrochemical processing of fibrinogen modified-graphite surfaces: effect on plasmin generation from adsorbed plasminogen.
    Alfonsi-Hourdin S; Longchamp S; Gallet O; Nigretto JM
    Biomaterials; 2006 Jan; 27(1):52-60. PubMed ID: 16029886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of fibrinogen and plasminogen concentrations in rabbits during anaphylactic shock.
    GANS H; KRIVIT W
    J Lab Clin Med; 1961 Aug; 58():259-67. PubMed ID: 13703370
    [No Abstract]   [Full Text] [Related]  

  • 5. Preparation of profibrinolysin-free fibrinogen and thrombin from human plasma.
    HINK JH; McDONALD JK
    Nature; 1962 Jun; 194():1080-1. PubMed ID: 13907542
    [No Abstract]   [Full Text] [Related]  

  • 6. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
    Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
    Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of ovarian function on the fibrinolytic enzyme system. I. Ovulatory and anovulatory cycles.
    TURKSOY RN; PHILLIPS LL; SOUTHAM AL
    Am J Obstet Gynecol; 1961 Dec; 82():1211-5. PubMed ID: 13923176
    [No Abstract]   [Full Text] [Related]  

  • 8. Antileukemic activity of glycated fibrinogen-methotrexate conjugates.
    Kanska U; Omar MS; Budzynska R; Nevozhay D; Jagiello M; Opolski A; Boratynski J
    Anticancer Res; 2005; 25(3B):2229-34. PubMed ID: 16158968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of endogenous plasma proteolytic enzymes with the consequent production of pharmacologically active polypeptides.
    MACKAY M; MAYCOCK WD; COMBRIDGE BS
    Nature; 1962 Sep; 195():1206-7. PubMed ID: 14467938
    [No Abstract]   [Full Text] [Related]  

  • 10. [Thermostable products forming during fibrinogen proteolysis by plasmin].
    Baskova IP; Kovaleva TB
    Biokhimiia; 1965; 30(4):734-8. PubMed ID: 4222714
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydrolysis of some casein fractions with plasmin.
    DERECHIN M
    Biochem J; 1962 Jan; 82(1):42-7. PubMed ID: 13885559
    [No Abstract]   [Full Text] [Related]  

  • 12. [APPLICATION OF IMMUNOCHEMICAL TECHNICS TO THE STUDY OF FIBRINOGEN AND ITS PRODUCTS OF DEGRADATION BY PLASMIN].
    SELIGMANN M; MARDER V
    Nouv Rev Fr Hematol; 1965; 5():345-54. PubMed ID: 14307707
    [No Abstract]   [Full Text] [Related]  

  • 13. [Fractionation and properties of early products of proteolysis of fibrinogen with the use of plasmin].
    Backova IP; Budzinskiĭ AZ
    Biokhimiia; 1965; 30(2):322-6. PubMed ID: 4222954
    [No Abstract]   [Full Text] [Related]  

  • 14. [Study of the physicochemical properties of fibrinogen M and fibrinolysin during prolonged storage at various temperatures].
    Karlova NG; Kashtanova MG; Krylova ND; Petrovskaia NN
    Probl Gematol Pereliv Krovi; 1973 Feb; 18(2):54-7. PubMed ID: 4271844
    [No Abstract]   [Full Text] [Related]  

  • 15. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences.
    Nowak P; Zbikowska HM; Ponczek M; Kolodziejczyk J; Wachowicz B
    Thromb Res; 2007; 121(2):163-74. PubMed ID: 17467041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen contains cryptic PAI-1 binding sites that are exposed on binding to solid surfaces or limited proteolysis.
    Smolarczyk K; Boncela J; Szymanski J; Gils A; Cierniewski CS
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2679-84. PubMed ID: 16210568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels.
    Smith JD; Chen A; Ernst LA; Waggoner AS; Campbell PG
    Bioconjug Chem; 2007; 18(3):695-701. PubMed ID: 17432824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Properties of human plasmin.
    RONWIN E
    Can J Biochem Physiol; 1962 Jan; 40():49-55. PubMed ID: 14493697
    [No Abstract]   [Full Text] [Related]  

  • 19. The kinetics of plasmin inhibition by aprotinin in vivo.
    Kang HM; Kalnoski MH; Frederick M; Chandler WL
    Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.